Finance

Lists
Why is ALLO down 6.48%?
Dive Deeper
ALLO:NASDAQ
Allogene Therapeutics Inc
US$0.70
-6.48%
(-0.048) 1D
US$0.74
+6.88% (+0.048)
Pre-market
Closed: ኖቬም 18, 4:00:01 ከሰዓት ጂ ኤም ቲ-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ALLO...
Open
US$0.76
High
US$0.78
Low
US$0.69
Mkt. cap
242.44 ሚ
Avg. vol.
9.92 ሚ
Volume
0.00
52-wk high
US$4.46
52-wk low
US$0.69
EPS
-US$0.62
Beta
0.76
Shares outstanding
346.47 ሚ
No. of employees
150
Open
US$0.76
High
US$0.78
Low
US$0.69
Mkt. cap
242.44 ሚ
Avg. vol.
9.92 ሚ
Volume
0.00
52-wk high
US$4.46
52-wk low
US$0.69
EPS
-US$0.62
Beta
0.76
Shares outstanding
346.47 ሚ
No. of employees
150
News stories
From web sources and news partners
About Allogene Therapeutics Inc
CEO-
Employees150
Founded2017
HeadquartersSouth San Francisco, ካሊፎርኒያ, ዩናይትድ ስቴትስ
SectorHealth Care
IndustryBiotechnology
Analyst ratings
Based on 4 analysts giving stock ratings to ALLO in the past 3 months
Strong buy
Buy
4
Hold
0
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for ALLO in the last 3 months.
Highest
Current US$0.70
US$14.00 (+1,911.78%)
Average
US$9.25 (+1,229.21%)
Lowest
US$4.00 (+474.80%)
Analyst
Recommendation
Action
Price target
Projected
Date
John Newman
Canaccord Genuity
Buy
Reiterated
US$14.00
+1,911.8%
11/10/2026
Samantha Semenkow
Citi
Buy
Maintained
US$4.00
+474.8%
11/09/2026
Luca Issi
RBC Capital
Buy
Maintained
US$9.00
+1,193.3%
11/05/2026
Biren Amin
Piper Sandler
Buy
Maintained
US$10.00
+1,337%
11/06/2026
Brian Cheng
J.P. Morgan
Hold
Maintained
-
-
08/17/2026
Tyler Van Buren
TD Cowen
Buy
Maintained
-
-
08/12/2026
Unknown Analyst
UBS
Buy
Reiterated
US$8.00
+1,049.6%
08/13/2026
Sami Corwin
William Blair
Buy
Maintained
-
-
08/13/2026
Matthew Biegler
Oppenheimer
Buy
Reiterated
US$7.00
+905.9%
05/14/2026
Roger Song
Jefferies
Buy
Maintained
US$10.00
+1,337%
04/15/2026
Jack Allen
Robert W. Baird
Buy
Maintained
US$9.00
+1,193.3%
04/14/2026
William Pickering
Bernstein
Hold
Maintained
US$3.85
+453.2%
04/14/2026
Robert Burns
H.C. Wainwright
Buy
Reiterated
US$11.00
+1,480.7%
04/16/2026
Reni Benjamin
Citizens JMP
Buy
Maintained
US$8.00
+1,049.6%
04/14/2026
Asthika Goonewardene
Truist Financial
Buy
Maintained
US$10.00
+1,337%
03/13/2026
Last report
6 ኖቬም 2026
Fiscal period
Q3 2026
-US$0.15 / -US$0.14
-6.50%miss
Revenue / Est. (USD)
0.00 / 2.22 ሺ
0.00%miss
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
ዲሴም 2025
ማርች 2026
ጁን 2026
ሴፕቴ 2026
Revenue
-
-
4.64 ሚ
-
Cost of goods sold
28.63 ሚ
32.00 ሚ
30.72 ሚ
41.93 ሚ
Cost of revenue
28.63 ሚ
32.00 ሚ
30.72 ሚ
41.93 ሚ
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
13.77 ሚ
14.09 ሚ
20.84 ሚ
12.86 ሚ
Operating expense
13.77 ሚ
14.09 ሚ
20.84 ሚ
12.86 ሚ
Total operating expenses
42.40 ሚ
46.09 ሚ
51.56 ሚ
54.79 ሚ
Operating income
-42.40 ሚ
-46.09 ሚ
-46.92 ሚ
-54.79 ሚ
Other non operating income
247.00 ሺ
212.00 ሺ
-61.00 ሺ
-76.00 ሺ
EBT including unusual items
-38.81 ሚ
-42.61 ሚ
-42.68 ሚ
-50.37 ሚ
EBT excluding unusual items
-38.81 ሚ
-42.61 ሚ
-42.68 ሚ
-50.37 ሚ
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-38.81 ሚ
-42.61 ሚ
-42.68 ሚ
-50.37 ሚ
Net profit margin
-
-
-919.76%
-
Earnings per share
-0.17
-0.18
-0.13
-0.15
Interest and investment income
3.66 ሚ
3.57 ሚ
4.65 ሚ
4.88 ሚ
Interest expense
-313.00 ሺ
-300.00 ሺ
-343.00 ሺ
-379.00 ሺ
Net interest expenses
3.35 ሚ
3.27 ሚ
4.30 ሚ
4.50 ሚ
Depreciation and amortization charges
-
-
-
-
EBITDA
-39.35 ሚ
-43.22 ሚ
-44.28 ሚ
-52.21 ሚ
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google መተግበሪያዎች